EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Modulating the microbiome as an approach to anticancer drug development

Jemma Arakelyan, Ho-Jung Choe, Chengnan Wu iD, Daniil A Rusanov iD, Elena E Bardina, Anna A Kirsanova iD, Yuliya V Zakalyukina iD, Nikita Y Shmelev, Anton P Tyurin iD, Vladislav Y Komarov iD, Vladimir Kushnarev, Nikolay S Karnaukhov und 8 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2417269122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Jemma Arakelyan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Drug Discovery Lab, City University of Hong Kong, Hong Kong Special Administrative Region 999077, People's Republic of China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Gastrointestinal Microbiome, Neoplasms, Drug Development. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pneumoconiosis Compensation Fund Board of Hong Kong, Russian Science Foundation (RSF), the Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent studies have suggested that the commensal microbiome positively affects cancer prognosis and treatment outcomes. However, only a few strategies for regulating the microbiome composition have been reported. In this study, we identified gold(I) complexes that selectively inhibited nonbeneficial bacterial strains in vitro without affecting commensal Lactobacillus strains. In contrast, clinically used drugs demonstrated comparable effects on both commensal and noncommensal strains. Consistent with the in vitro results, the selected gold(I) complex induced favorable changes in the intratumoral and gastrointestinal microbiomes in vivo. Furthermore, its anticancer efficacy was found to be dependent on the composition of microbiome and correlated with the production of short-chain fatty acid bacterial metabolites. Structure–activity relationship studies have dissected the contribution of each structural component in both the in vivo efficacy and microbiome-modulating properties. Transcriptomic analysis of tumors revealed microbiome-associated gene signaling pathways. These findings provide valuable insights for future research on microbiome-modulating anticancer drugs, presenting potential avenues to optimize cancer treatment outcomes and mitigate side effects such as gastrointestinal dysbiosis. Furthermore, our study provides insights into the involvement of microbiome in the mechanism of action of metal-based chemotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsGastrointestinal MicrobiomeNeoplasmsDrug DevelopmentMicrobiotaAnimalsMiceHumansCell Line, TumorFemale

Stichwörter der Autor:innen

anticancer therapeuticsbioinorganicgold complexmicrobiometumor microenvironment

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemistry, Drug Discovery Lab, City University of Hong Kong, Hong Kong Special Administrative Region 999077, People's Republic of China.
  • A.V. Nikolaev Institute of Inorganic Chemistry, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Russian Federation.
  • Department of Soil Science, Lomonosov Moscow State University, Moscow 119991, Russian Federation.
  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russian Federation.
  • Moscow Clinical Research Center named after A.S. Loginov, Moscow 111123, Russian Federation.
  • N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Russian Federation.

ORCID-Profile: Chengnan Wu, Daniil A Rusanov, Anna A Kirsanova, Yuliya V Zakalyukina, Anton P Tyurin, Vladislav Y Komarov, Eugene S Vasilyev, Eunice Dotse, Kwan T Chow, William C Cho, Maria V Babak

Förderung

  • Pneumoconiosis Compensation Fund Board of Hong Kong
  • Russian Science Foundation (RSF)
  • the Ministry of Science and Higher Education of the Russian Federation
  • Croucher Foundation
  • Hong Kong Research Grants Council

Zitieren

APA

Arakelyan, J., Choe, H. J., Wu, C., Rusanov, D. A., Bardina, E. E., Kirsanova, A. A., Zakalyukina, Y. V., Shmelev, N. Y., Tyurin, A. P., Komarov, V. Y., Kushnarev, V., Karnaukhov, N. S., D'Cruz, G., Vasilyev, E. S., Dotse, E., Chow, K. T., Cho, W. C., Tkachev, A. V., Gushchin, A. L., & Babak, M. V. (2025). Modulating the microbiome as an approach to anticancer drug development. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2417269122

Vancouver

Arakelyan J, Choe HJ, Wu C, Rusanov DA, Bardina EE, Kirsanova AA, et al. Modulating the microbiome as an approach to anticancer drug development. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2417269122

BibTeX
@article{Arakelyan2025,
  author = {Arakelyan, Jemma and Choe, Ho-Jung and Wu, Chengnan and Rusanov, Daniil A and Bardina, Elena E and Kirsanova, Anna A and Zakalyukina, Yuliya V and Shmelev, Nikita Y and Tyurin, Anton P and Komarov, Vladislav Y and Kushnarev, Vladimir and Karnaukhov, Nikolay S and D'Cruz, Gerald and Vasilyev, Eugene S and Dotse, Eunice and Chow, Kwan T and Cho, William C and Tkachev, Alexey V and Gushchin, Artem L and Babak, Maria V},
  title = {Modulating the microbiome as an approach to anticancer drug development},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2417269122}
}
Kostenlos starten →